Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
France
(1,043/week)
Czechia
(459/week)
Poland
(318/week)
Italy
(315/week)
Germany
(302/week)
View all
(3,747/week)
News
United States
(447/week)
Manufacturing
(324/week)
Energy
(233/week)
Technology
(367/week)
Other Manufacturing
(249/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Menstruation
Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar 09, 2020
The global premenstrual syndrome treatment market was valued at $1,129 million in 2018, and is projected to reach $1,516 million by 2026, registering a CAGR of 3.7% from 2019 to 2026
Jan 31, 2020
California AB 1989 Will Allow Manufacturers of Period Care Products to Continue to Hide Ingredients
Jan 29, 2020
Adore Me introduces Joyja - an ultra-inclusive brand of period panties
Dec 04, 2019
Study Finds Key Brain Region Smaller in Birth Control Pill Users
Sep 25, 2019
Aleve® Demonstrates More Pain Relief Than Acetaminophen for Menstrual Cramps, Study Shows
May 20, 2019
Ava Unveils Unprecedented Insights Into Physical Changes During Menstrual Cycle That Can Be Used to Accurately Identify Fertile Window
Oct 08, 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Aug 09, 2018
Global Menstrual Cup (Disposable & Reusable) Market 2018-2022
Jul 10, 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Apr 24, 2018
Women's Health Company Hologic and Actor, Director Aisha Tyler Partner to Help the One in Five Women Suffering in Silence with Heavy Periods
Nov 17, 2017
Menstrual Cups Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2015 - 2023
Nov 09, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
Oct 02, 2017
Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids
Latest News
Dec 7, 2023
4th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award Launched
Dec 7, 2023
SiTime Solves Critical Challenges in GPS-enabled Defense Systems
Dec 7, 2023
Global Smart Vineyard and Orchard Equipment Market Analysis and Forecast Report 2023-2028 -...
Dec 7, 2023
Nodal Exchange achieves year over year growth in all markets
Dec 7, 2023
Cosmo Energy Holdings Corporation and Domo Develop Data Education Workshops and Internships at Shiga...
Dec 7, 2023
Jason Cherry Joins Assent as New Chief Financial Officer
Dec 7, 2023
Cabot Corporation Named to Newsweek’s America’s Most Responsible Companies 2024 List
Dec 7, 2023
Lineage Joins Newly Formed Global Coalition Pioneering Sustainable and Safe Frozen Food Solutions Alongside...
View all News
Agenda
23
April
Denmark
Scandic Sluseholmen, Copenhagen, Denmark
Arctic Security conference, 23 - 24 April 2024, Scandic Sluseholmen, Copenhagen, Denmark
Defence iQ are proud to present Arctic Security conference taking place on 23 - 24 April, 2024 at Scandic Sluseholmen,...
13
March
Copthorne Tara, London, UK
Deployed Medical Healthcare Delivery, 13 - 14 March 2024, Copthorne Tara, London, UK
This two-day event will address military medical capability is increasingly relevant within the context of attritional...
05
March
United States of America
Sheraton Austin Hotel at the Capitol, Austin, Texas
IDGA Future Indirect Fires conference, 5 - 6 March 2024, Sheraton Austin Hotel at the Capitol, Austin, Texas
IDGA are proud to present the return of the Future Indirect Fires conference taking place on March 5-6, 2024 in...
View All Events